CymaBay Therapeutics Future Growth
Future criteria checks 2/6
CymaBay Therapeutics is forecast to grow earnings and revenue by 49.8% and 49.8% per annum respectively. EPS is expected to grow by 50.4% per annum. Return on equity is forecast to be -50.1% in 3 years.
Key information
49.8%
Earnings growth rate
50.4%
EPS growth rate
Pharmaceuticals earnings growth | 14.8% |
Revenue growth rate | 49.8% |
Future return on equity | -50.1% |
Analyst coverage | Good |
Last updated | 22 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 252 | -61 | -5 | N/A | 6 |
12/31/2025 | 108 | -164 | -68 | N/A | 7 |
12/31/2024 | 12 | -158 | -18 | -122 | 8 |
12/31/2023 | 31 | -105 | -73 | -73 | N/A |
9/30/2023 | 31 | -90 | -64 | -64 | N/A |
6/30/2023 | 31 | -81 | -56 | -55 | N/A |
3/31/2023 | N/A | -107 | -53 | -52 | N/A |
12/31/2022 | N/A | -106 | -84 | -84 | N/A |
9/30/2022 | N/A | -106 | -80 | -80 | N/A |
6/30/2022 | N/A | -104 | -78 | -77 | N/A |
3/31/2022 | N/A | -100 | -74 | -74 | N/A |
12/31/2021 | N/A | -90 | -70 | -69 | N/A |
9/30/2021 | N/A | -79 | -70 | -70 | N/A |
6/30/2021 | N/A | -68 | -62 | -62 | N/A |
3/31/2021 | N/A | -55 | -51 | -51 | N/A |
12/31/2020 | N/A | -51 | -45 | -45 | N/A |
9/30/2020 | N/A | -65 | -58 | -58 | N/A |
6/30/2020 | N/A | -80 | -74 | -74 | N/A |
3/31/2020 | N/A | -93 | -90 | -90 | N/A |
12/31/2019 | N/A | -103 | -98 | -98 | N/A |
9/30/2019 | N/A | -93 | -90 | -89 | N/A |
6/30/2019 | N/A | -85 | -83 | -82 | N/A |
3/31/2019 | N/A | -79 | -72 | -71 | N/A |
12/31/2018 | N/A | -73 | -55 | -55 | N/A |
9/30/2018 | 5 | -58 | -41 | -41 | N/A |
6/30/2018 | 5 | -48 | -31 | -31 | N/A |
3/31/2018 | 5 | -39 | -24 | -24 | N/A |
12/31/2017 | 10 | -28 | -20 | -20 | N/A |
9/30/2017 | 5 | -29 | N/A | -19 | N/A |
6/30/2017 | 5 | -27 | N/A | -19 | N/A |
3/31/2017 | 5 | -25 | N/A | -19 | N/A |
12/31/2016 | N/A | -27 | N/A | -23 | N/A |
9/30/2016 | N/A | -26 | N/A | -23 | N/A |
6/30/2016 | N/A | -26 | N/A | -24 | N/A |
3/31/2016 | N/A | -20 | N/A | -23 | N/A |
12/31/2015 | N/A | -16 | N/A | -23 | N/A |
9/30/2015 | N/A | -22 | N/A | -26 | N/A |
6/30/2015 | N/A | -22 | N/A | -23 | N/A |
3/31/2015 | N/A | -24 | N/A | -22 | N/A |
12/31/2014 | N/A | -32 | N/A | -21 | N/A |
9/30/2014 | N/A | 208 | N/A | -17 | N/A |
6/30/2014 | N/A | 257 | N/A | -14 | N/A |
3/31/2014 | N/A | 240 | N/A | -11 | N/A |
12/31/2013 | N/A | 244 | N/A | -8 | N/A |
9/30/2013 | 0 | 11 | N/A | -5 | N/A |
6/30/2013 | 3 | -36 | N/A | -8 | N/A |
3/31/2013 | 3 | -23 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0I5P is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0I5P is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0I5P is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0I5P's revenue (49.8% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0I5P's revenue (49.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0I5P is forecast to be unprofitable in 3 years.